Slides
Page 1
1H FY25 Results 2 September 2025 For personal use only
Page 2
THE RADIOLOGY OF THE FUTURE delivered into your hands 01 For personal use only
Page 3
One Company with two businesses aimed at democratizing access to medical imaging expertise Software Business Medical imaging software (RIS, PACS, universal viewer, AI) Radiology Services Radiology services, primarily in Colombia 02 For personal use only
Page 4
8.9M Imaging studies year +549 Installed sites 3.4K Monthly Specialist users 6.3M Users of the patient portal 25 Partners 58 Net Promoter Score Some Figures 03 For personal use only
Page 5
2020 2021 2022 2023 2024 Studies Per Year (M) 6 7.8 8.0 8.4 8.9 Portal Users (M) - 2.5 3.5 6.4 6.7 Sites 270 386 449 485 525 2020 2021 2022 2023 2024 0 100 200 300 400 500 600 - 1 2 3 4 5 6 7 8 9 10 TRENDS LAST 5 YEARS 04 5 YEAR OVERVIEW TRENDS For personal use only
Page 6
Our certifications reaffirm our dedication to excellence across multiple geographies. IMEXHS GLOBAL PRESENCE 05 For personal use only
Page 7
1H FY25 FINANCIAL HIGHLIGHTS06 $13.7m Sales Revenue1 Up 4% yoy Up 7% on a constant currency basis2 $32.8m Annual Recurring Revenue (ARR) Up 11% yoy Up 7% on a constant currency basis Underlying EBITDA3 Flat vs pcp $2.5m Cash $1.3m Debt 1. Excluding the one-off sale of $0.7m in pcp. 2. Constant currency basis assumes H1 FY25 results are converted at the average foreign exchange rate for 1H FY24. This removes the impact of changes in currency rates and allows comparison of IMEXHS’s underlying operating performance. 3. Underlying EBITDA excludes the impact of FX, share based payments and the impairment of goodwill of $1.7m in 1H FY25. $0.3m vs $1.2m at 31 December 2024 vs $2.1m at 31 December 2024 For personal use only
Page 8
1H FY25 BUSINESS UNIT RESULTS07 Software primarily relates to sales of IMEXHS Enterprise and growing IMEXHS Cloud business → Revenue up 11% vs pcp (excluding the one-off sale of $0.7m in pcp) → ARR up 20% vs pcp → Underlying EBITDA of $1.3m down from $1.9m in pcp $M Software Radiology Corporate Total 1H FY25 Revenue 4.7 9.0 - 13.7 Underlying EBITDA 1.3 0.3 (1.3) 0.3 ARR 11.9 20.9 - 32.8 Radiology includes RIMAB along with other services related to outsourcing radiology on- premise or remotely using IMEXHS software → Revenue up 1% vs pcp. → ARR up 6% vs pcp. → Underlying EBITDA of $0.3m up vs ($0.2m) in pcp. → Corporate costs of $1.3m down $0.1m vs $1.4m in pcp For personal use only
Page 9
PROGRESS IN ARR08 (1) Constant currency basis assumes that historical results at each year end are converted at the 30 Jun-25 exchange rate. This removes the impact of changes in currency rates and allows comparison of IMEXHS’s underlying operating performance. (2) Adjustments to ARR are made as contracts move from estimates to actual volumes and as estimates are removed for any older contracts which are assessed as unlikely to proceed. ARR AS AT 30 JUNE 2025 → $32.8m, up 11% vs 30 Jun-24: → $32.8m, up 9% vs 31 Dec-24 → $11.9m from Software, up 20% vs $9.9m at 31 Dec-24; and → $20.9m from Radiology services, up 4% vs $20.1m at 31 Dec-24. For personal use only
Page 10
Delivering diagnoses that transform the lives of 500 million people. We are dedicated to offering tailored technology and service solutions to hospitals, clinics, and diagnostic centres, with a clear emphasis on improving radiology efficiency and lowering costs by up to 80%. 09 For personal use only
Page 11
SOFTWARE BUSINESS STRATEGY- IMEXHS LATAM Leadership SaaS Model Trust & Reliability Efficiency 10 For personal use only
Page 12
Driving sustainable, efficient, and profitable growth STRATEGIC PILLARS Consolidate leadership in LATAM Scale SaaS MODEL Driving automation and cost efficiency STRATEGIC PILLARS11 For personal use only
Page 13
SOFTWARE BUSINESS HIGHLIGHTS - IMEXHS12 SOFTWARE ARR → $11.9m ARR and $4.7m revenue at 1H FY25. → Driven by Aquila+ adoption and strong retention ENTERPRISE WINS → Q1: $183k Clínica Occidente + Hospital Moncaleano. → Q2: $206k INNN México + $490K Diodiagnostico (extension). PARTNERS CHANNEL → 25 partners in 15 countries. → 33% of 1H NARR generated by partners (vs 11% in 1H FY24) SOFTWARE FOOTPRINT → 549 live sites in 18 countries. → ~2.1M studies processed per quarter COMMERCIAL DISCIPLINE → Segment-specific pricing launched → Cost optimization in cloud, storage, workflow For personal use only
Page 14
SOFTWARE PRODUCT13 Product Progress → Launch of Aquila+ • A fully integrated multitenant RIS-PACS AI-enhanced suite. • Transcription & validation module implemented. • Smart routing worklist launched. • Auto refresh, automatic viewer opening. • AI chat assistant for radiologist and coin counter (productivity). • Integrations enabled with AI 3rd parties: AI prioritization within worklist, for DeepC and Entelai. New Value Proposition → Fully Deployed • Cybersecurity: ISO 27001 certification achieved for the Aquila+, and R&D process. • Quick and easy implementation process (60% faster vs Aquila 3). • Modern update cadency (biweekly frequency, no downtime). • Support service with CES (Customer Effort Score) of 6.4 / 7.0, in the top quintile of the industry. • +5 new features enabled by AI. For personal use only
Page 15
14 For personal use only
Page 16
15 For personal use only
Page 17
COST & MARGIN IMPROVEMENT IN 1H 16 Structured plan to strengthen EBITDA & Margins AREA KEY ACTION Cloud Costs (storage and processing) reduced, improvements in gross margin. R&D / Product Focus on key processes and value creation. Finance Optimized structure, impact on fixed costs. Sales Admin Adjusted administrative costs. EBITDA Projected improvement of 8–9% since H2. Next Steps Continuous assessment of new efficiencies. For personal use only
Page 18
NEW SOFTWARE PRICING MODEL17 Market Segmentation Strategy → Four Distinct Segments → Customized Value Propositions Pricing Model Innovation → Customer-Centric Pricing → Implementation Roadmap Projected Financial Impact → Pricing Model Benefits → Profit Margin Improvement Upselling Opportunity → Secondary Revenue → Leveraging Aquila+ Product For personal use only
Page 19
SOFTWARE BUSINESS - IMEXHS18 Commercial Execution New segmentation + pricing model Partners Program Boost Pipeline & Sales Conversion Expansion Plan 2025 Focus on 2026 Entry plans Enhanced Partner Support 2025 - 2026 For personal use only
Page 20
RADIOLOGY SERVICES - RIMAB19 • Diagnostics Precision. • Services Scalability. • AI Adoption. • 35 sites. • Specialized Staff - 160 radiologists. • 110k procedures per month • Revenue $9.0m • EBITDA $281k • ARR $20.9m • Outsorcing • Teleradiology. • Outpatient clinics. • Mobile units. Business Model Financial Snapshot Tech Integration Operating Footprint For personal use only
Page 21
STRATEGY – RADIOLOGY BUSINESS - RIMAB20 Profitability Working Capital Context Colombia’s Healthcare Sector Structural crisis, pending reforms. Regulatory uncertainty, increased financial stress on payors. Delayed payments and high working capital risk. RIMAB ACTIONS Continue improving margins. Strategic customers selection and active contract negotiation. Protect working capital – strict credit terms. For personal use only
Page 22
STRATEGIC OUTLOOK21 Regional consolidation and growth • Commercial and marketing focus on selected segments. Pricing optimization (new model) • To improve margins and sales efficiency. Value Proposition Enhancement • Upselling Aquila+ to current customers and aligning offerings with market trends. Pipeline, ARR and revenue growth • Accelerate growth thorough funnel expansion. Margins Improvement • Dynamic pricing assessment and renegotiation. • Cost control via AI and automation. Working capital protection • Tightening of credit terms. • Exit contracts with customers under financial distress. Financial Discipline Focus • Improve liquidity and cash level. Risk Reduction Strategies • Lowering exposure to distressed healthcare payors. Software Business Radiology Services For personal use only
Page 23
22 Guidance The Company expects to achieve the following for FY25: → Revenue in the range $27.5m to $28.2m - up 4.0 to 6.6% vs prior year. → Underlying EBITDA in the range $1.3m to $1.6m - up $0.8m to $1.1m vs prior year. FY25 GUIDANCE For personal use only
Page 24
THANK YOU For personal use only
Page 25
Q&A For personal use only
Page 26
The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and conditions set out in this notice. The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. The Information may not be appropriate for all persons and it is not possible for ImExHS Limited to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information. Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information. Past performance detailed in this presentation is given for illustrative purposes only and should not be relied upon as an indication of the Company’s views on its future financial performance or condition. Readers should note that past performance of the Company cannot be relied upon as an indicator of (and provides no guidance as to) future performance, including the future trading price of the Company’s shares, or the reasonableness of any forward looking statements, forecast financial information or other forecast. Actual results could differ materially from those referred to in the presentation. Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of ImExHS Limited are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and ImExHS Limited may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information. To the maximum extent permitted by law none of ImExHS Limited or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information. All financial information in this presentation is in Australian Dollars ($ or AUD) unless otherwise stated. Investors should be aware that certain financial measures included in this presentation are ‘non-IFRS financial information’ under ASIC Regulatory Guide 230: ‘Disclosing non- IFRS financial information’ published by ASIC and are not recognised under International Financial Reporting Standards (IFRS). The principal non-IFRS financial measures that are referred to in this presentation is EBITDA. EBITDA is earnings before interest, tax, depreciation and amortisation and significant items. Management uses EBITDA to evaluate the operating performance of the business prior to the impact of significant items, the non-cash impact of depreciation and amortisation and interest and tax charges. The Company believes the non-IFRS financial information provides useful information to users in measuring the financial performance and conditions of the Company. The non-IFRS financial information does not have a standardised meaning prescribed by IFRS. Therefore, the non-IFRS financial information is not a measure of financial performance, liquidity or value under the IFRS and may not be comparable to similarly titled measures presented by other entities, and should not be construed as an alternative to other financial measures determined in accordance with IFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial information included in this presentation. Disclaimer For personal use only
Page 27
1H FY25 Results 2 September 2025 For personal use only